Katharine and Skye had never met each other, but they shared something in common. Both women carry the BRCA-1 gene mutation. This is an inherited gene that increases their chance of developing breast cancer by 70% and ovarian cancer by 40% throughout their lifetime.

Until now, life-changing invasive surgery and regular breast screening have been the only options available for women like Katharine and Skye. However, the BRCA-P clinical trial aims to open up a new treatment opportunity for women with this gene mutation.

BRCA-P is a preventative trial, which is testing the effectiveness of a drug called Denosumab in preventing breast cancer for these women.